Skip to main content
MedPathMedPath Home
Clinical Trials/CTIS2024-512642-42-00
CTIS2024-512642-42-00
Recruiting
Phase 1

Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pediatric patients with Hodgkin lymphoma and non-Hodgkin lymphoma needing radiation therapy on thyroid site - WINHYPO 2021

Fondazione IRCCS Istituto Nazionale Dei Tumori0 sites65 target enrollmentMarch 18, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHodgkin and non Hodgkin lymphoma, MedulloblastomaTherapeutic area: Diseases [C] - Neoplasms [C04]

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hodgkin and non Hodgkin lymphoma, Medulloblastoma
Sponsor
Fondazione IRCCS Istituto Nazionale Dei Tumori
Enrollment
65
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Any patient with medulloblastoma, Hodgkin/non\-Hodgkin Lymphoma BEFORE RADIOTHERAPY (RT) PLANNING INCLUDING THYROID PARENCHYMA without previous primary or secondary hypothyroidism;, Written informed consent prior to any study\-specific analysis and/or data collection.

Exclusion Criteria

  • •Any patient with medulloblastoma, Hodgkin/non\-Hodgkin Lymphoma after radiotherapy including thyroid parenchyma;, Not signed consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA NEEDING RADIATION THERAPY ON THYROID SITE
EUCTR2021-001385-38-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI51
Recruiting
Not Applicable
Radiation Protection Effects of Metformin in Prostate CancerProstate cancer.Malignant neoplasm of prostate
IRCT20170307032933N3Ahvaz University of Medical Sciences60
Not yet recruiting
Not Applicable
In this study the Sun Protection Factor of SPF will be determined.
CTRI/2019/01/017283Sami Labs Limited
Completed
Not Applicable
A study to check the sun protection benefits
CTRI/2023/02/049856nilever Industries Pvt Ltd10
Completed
Phase 2
A study to determine the protection factor of a test product against sun rays.
CTRI/2021/04/032696ITC Life Sciences Technology Centre20